Michael E Prevoznik Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 12 hours ago
Michael E Prevoznik has an estimated net worth of at least $26.7 million*, as of Dec. 11, 2024. They own 38,478 shares of DGX stock. They have sold 139,232 shares of DGX stock since 2021, for an estimated $20.7 million.
Michael E Prevoznik $DGX SEC Form 4 Insider Trading
Michael E Prevoznik has filed a total of 11 insider trades in $DGX since 2021. Their most recent trade was a sale of 3,009 shares, made on Nov 29, 2024. Their largest trade was a sale of 50,604 shares, made on May 17, 2022. We estimate that they now own 38,478 shares of $DGX, worth an estimated $6.1 million.
Insider Trading at $DGX
There have been a total of 67 insider trades reported at $DGX since 2021, with 0 shares purchased and 915,280 shares sold. The most active insider traders in $DGX stock have been Stephen H Rusckowski, Michael E Prevoznik, and Catherine T. Doherty. The most recent trade was a sale of 3,009 shares reported by MICHAEL E PREVOZNIK (SVP & General Counsel), made on Nov 29, 2024.
History of Insider Stock Trades by Michael E Prevoznik
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
DGX | Sale | 3,009 | Nov 29, 2024 | Dec. 2, 2024, 5:43 p.m. |
DGX | Sale | 32,137 | Nov 29, 2024 | Dec. 2, 2024, 5:43 p.m. |
DGX | Sale | 32,551 | Aug 29, 2024 | Sept. 3, 2024, 4:30 p.m. |
DGX | Sale | 5,611 | Feb 29, 2024 | March 1, 2024, 5:50 p.m. |
DGX | Sale | 661 | Feb 22, 2024 | Feb. 23, 2024, 5:35 p.m. |
DGX | Sale | 4,754 | Mar 07, 2023 | March 8, 2023, 5:39 p.m. |
DGX | Sale | 593 | Mar 02, 2023 | March 3, 2023, 5:51 p.m. |
DGX | Sale | 1,415 | Feb 24, 2023 | Feb. 27, 2023, 5:49 p.m. |
DGX | Sale | 50,604 | May 17, 2022 | May 19, 2022, 4:40 p.m. |
DGX | Sale | 6,228 | Mar 08, 2022 | March 9, 2022, 5:50 p.m. |
DGX | Sale | 1,669 | Feb 24, 2022 | Feb. 28, 2022, 8:35 p.m. |
$DGX Executives and Stock Owners with Insider Trades
-
Stephen H Rusckowski, Chairman, CEO and President
-
Michael E Prevoznik, SVP & General Counsel
-
Catherine T. Doherty, SVP, Group Exec. Clin. Fran.
-
Michael J Deppe, SVP, Corp. Controller & CAO
-
Catherine T. Doherty, EVP, Regional Businesses
-
Catherine T. Doherty, SVP, Regional Businesses
-
Karthik Kuppusamy, SVP, Clinical Solutions
-
Mark E Delaney, SVP & Chief Commercial Officer
-
Michael J Deppe, VP, Corp. Controller & CAO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.